MAPK7 and neoplasm: SKLB-D18 not only exhibited highly selective inhibition of ERK1/2 and ERK5 but also demonstrated more significant anti-tumor activity than clinical ERK1/2 inhibitor BVD-523 in vivo assays, and possessed acceptable pharmacokinetic properties.